• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
LPCN

LPCN

Lipocine Inc.

NASDAQHealthcareBiotechnologyUS

USD2.19

-0.06 (-2.67%)

Rating:C

Company Profile

CEO

Mahesh V. Patel

IPO Date

2013-10-22

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$2.23

Prev. Close

$2.25

Day Low

$2.18

Day High

$2.24

52W Low

$1.81

52W High

$12.37

Market Cap

$0.01B

Volume

0.06M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

28.6%

Avg Negative

12.3%

Avg Neutral

59.0%

News Feed

Lipocine Stock Jumps On Litigation Settlement With Clarus Therapeutics

Benzinga·7/15/2021·↑ positive

Lipocine Announces Settlement With Clarus Therapeutics

PRNewsWire·7/14/2021·↑ positive

Lipocine To Present At The Ladenburg Thalmann Healthcare Conference

PRNewsWire·7/6/2021·↑ positive

Lipocine To Present At The Raymond James Human Health Innovation Conference

PRNewsWire·6/16/2021·↑ positive

Lipocine To Start Testing Neuro-Steroid Candidate In Postpartum Depression Patients

Benzinga·6/14/2021·↑ positive

FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study

PRNewsWire·6/14/2021·↑ positive

Lipocine to Present at the Lytham Partners Summer 2021 Investor Conference

PRNewsWire·6/7/2021·↑ positive

Summary Judgment Ruling in Patent Infringement Lawsuit

PRNewsWire·5/26/2021·↓ negative

Clarus Therapeutics Defeats Lipocine's Patent Infringement Lawsuit On Summary Judgment

PRNewsWire·5/25/2021·↓ negative

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021

PRNewsWire·5/6/2021·↑ positive